Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study)

References

1. 1.↵
   2. Rohrer M,
   3. Bauer H,
   4. Mintorovitch J, et al

   . Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40:715–24 doi:10.1097/01.rli.0000184756.66360.d3 pmid:16230904

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Anzalone N,
   3. Scarabino T,
   4. Venturi C, et al

   . Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting. Eur J Radiol 2013;82:139–45 doi:10.1016/j.ejrad.2011.07.005 pmid:21890295

   CrossRefPubMed
3. 3.↵
   2. Maravilla KR,
   3. Smith MP,
   4. Vymazal J, et al

   . Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study). AJNR Am J Neuroradiol 2015;36:14–23 doi:10.3174/ajnr.A4154 pmid:25300984

   Abstract/FREE Full Text
4. 4.↵
   2. Katakami N,
   3. Inaba Y,
   4. Sugata S, et al

   . Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases. Invest Radiol 2011;46:411–18 doi:10.1097/RLI.0b013e3182145a6c pmid:21467949

   CrossRefPubMed
5. 5.↵
   2. Oudkerk M,
   3. Sijens PE,
   4. Van Beek EJ, et al

   . Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 1995;30:75–78 doi:10.1097/00004424-199502000-00002 pmid:7782190

   CrossRefPubMed
6. 6.↵
   2. Desché P

   . Re: cerebral neoplastic enhancing lesions—multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting. Eur J Radiol 2012;81:e967; author reply 2925–26 doi:10.1016/j.ejrad.2012.04.015 pmid:22578838

   CrossRefPubMed
7. 7.↵
   2. de Kerviler E,
   3. Maravilla K,
   4. Meder JF, et al

   . Adverse reactions to gadoterate meglumine: review of over 25 years of clinical use and more than 50 million doses. Invest Radiol 2016;51:544–51 doi:10.1097/RLI.0000000000000276 pmid:27504794

   CrossRefPubMed
8. 8.↵
   2. Endrikat J,
   3. Vogtlaender K,
   4. Dohanish S, et al

   . Safety of gadobutrol: results from 42 clinical phase II to IV studies and postmarketing surveillance after 29 million applications. Invest Radiol 2016;51:537–43 doi:10.1097/RLI.0000000000000270 pmid:26964075

   CrossRefPubMed
9. 9.↵
   2. Grobner T

   . Gadolinium–a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104–08 pmid:16431890

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Marckmann P,
    3. Skov L,
    4. Rossen K, et al

    . Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359–62 doi:10.1681/ASN.2006060601 pmid:16885403

    Abstract/FREE Full Text
11. 11.↵
    2. Kanda T,
    3. Ishii K,
    4. Kawaguchi H, et al

    . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844

    CrossRefPubMed
12. 12.↵
    2. Kanda T,
    3. Fukusato T,
    4. Matsuda M, et al

    . Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015;276:228–32 doi:10.1148/radiol.2015142690 pmid:25942417

    CrossRefPubMed
13. 13.↵
    2. McDonald RJ,
    3. McDonald JS,
    4. Kallmes DF, et al

    . Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275:772–82 doi:10.1148/radiol.15150025 pmid:25742194

    CrossRefPubMed
14. 14.↵
    2. Radbruch A,
    3. Weberling LD,
    4. Kieslich PJ, et al

    . Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015;275:783–91 doi:10.1148/radiol.2015150337 pmid:25848905

    CrossRefPubMed
15. 15.↵
    2. Radbruch A,
    3. Haase R,
    4. Kieslich PJ, et al

    . No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR images after more than 20 serial injections of macrocyclic gadolinium-based contrast agents. Radiology 2017;282:699–707 doi:10.1148/radiol.2016162241 pmid:27925871

    CrossRefPubMed
16. 16.↵
    2. Cao Y,
    3. Huang DQ,
    4. Shih G, et al

    . Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. AJR Am J Roentgenol 2016;206:414–19 doi:10.2214/AJR.15.15327 pmid:26700156

    CrossRefPubMed